Concepts (100)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 5 | 2014 | 335 | 0.420 |
Why?
|
| Thioctic Acid | 2 | 2014 | 12 | 0.230 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2022 | 20 | 0.200 |
Why?
|
| Fatigue | 2 | 2013 | 194 | 0.190 |
Why?
|
| Antioxidants | 2 | 2014 | 336 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2019 | 28 | 0.170 |
Why?
|
| Pyridazines | 1 | 2019 | 51 | 0.160 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2019 | 93 | 0.160 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 64 | 0.160 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2020 | 185 | 0.150 |
Why?
|
| Piperidines | 1 | 2019 | 204 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 287 | 0.140 |
Why?
|
| Pyrimidines | 1 | 2019 | 372 | 0.130 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 2016 | 61 | 0.130 |
Why?
|
| Disability Evaluation | 2 | 2014 | 193 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 359 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 375 | 0.120 |
Why?
|
| Adenoma | 1 | 2016 | 135 | 0.120 |
Why?
|
| Vitamins | 1 | 2012 | 107 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2012 | 72 | 0.090 |
Why?
|
| Vitamin D | 1 | 2012 | 159 | 0.090 |
Why?
|
| Psychometrics | 1 | 2012 | 676 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2013 | 803 | 0.080 |
Why?
|
| Cytokines | 1 | 2014 | 1290 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 938 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 4356 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2784 | 0.060 |
Why?
|
| Depression | 1 | 2012 | 1244 | 0.060 |
Why?
|
| Surveys and Questionnaires | 1 | 2012 | 3725 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 212 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2020 | 49 | 0.040 |
Why?
|
| Double-Blind Method | 2 | 2014 | 1630 | 0.040 |
Why?
|
| Genome, Viral | 1 | 2020 | 167 | 0.040 |
Why?
|
| Nausea | 1 | 2019 | 85 | 0.040 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 141 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 158 | 0.040 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 150 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2020 | 393 | 0.040 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2020 | 191 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2019 | 388 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 107 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 694 | 0.040 |
Why?
|
| Young Adult | 3 | 2019 | 8976 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 242 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2022 | 820 | 0.040 |
Why?
|
| Adult | 5 | 2019 | 29407 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2020 | 1075 | 0.030 |
Why?
|
| Humans | 9 | 2022 | 124502 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 464 | 0.030 |
Why?
|
| Diethylnitrosamine | 1 | 2016 | 17 | 0.030 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 25 | 0.030 |
Why?
|
| Swine, Miniature | 1 | 2016 | 46 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 2701 | 0.030 |
Why?
|
| Embolism | 1 | 2016 | 48 | 0.030 |
Why?
|
| Base Sequence | 1 | 2020 | 3097 | 0.030 |
Why?
|
| Portal Vein | 1 | 2016 | 92 | 0.030 |
Why?
|
| STAT5 Transcription Factor | 1 | 2016 | 90 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1688 | 0.030 |
Why?
|
| Growth Hormone | 1 | 2016 | 153 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 530 | 0.030 |
Why?
|
| alpha-Fetoproteins | 1 | 2016 | 132 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 398 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 134 | 0.030 |
Why?
|
| Genotype | 1 | 2020 | 2551 | 0.030 |
Why?
|
| Female | 6 | 2019 | 66333 | 0.030 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2016 | 339 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 221 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 3426 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 420 | 0.030 |
Why?
|
| Malondialdehyde | 1 | 2013 | 35 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 411 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2013 | 32 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2013 | 139 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1105 | 0.030 |
Why?
|
| Iran | 1 | 2012 | 59 | 0.030 |
Why?
|
| Swine | 1 | 2016 | 1173 | 0.030 |
Why?
|
| Fasting | 1 | 2014 | 299 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2022 | 2608 | 0.030 |
Why?
|
| Male | 5 | 2019 | 61062 | 0.020 |
Why?
|
| Middle Aged | 3 | 2019 | 26526 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 817 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 678 | 0.020 |
Why?
|
| Texas | 1 | 2020 | 3588 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 775 | 0.020 |
Why?
|
| Activities of Daily Living | 1 | 2012 | 404 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2012 | 812 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2012 | 872 | 0.020 |
Why?
|
| Sex Factors | 1 | 2013 | 1276 | 0.020 |
Why?
|
| Aged | 2 | 2019 | 19560 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6487 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2012 | 2127 | 0.020 |
Why?
|
| Age Factors | 1 | 2013 | 2810 | 0.020 |
Why?
|
| Time Factors | 1 | 2016 | 6285 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2869 | 0.020 |
Why?
|
| Adolescent | 2 | 2014 | 19303 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3269 | 0.020 |
Why?
|
| Biomarkers | 1 | 2013 | 2990 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2012 | 2898 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12322 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34157 | 0.010 |
Why?
|